You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

GALANTAMINE HYDROBROMIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Galantamine Hydrobromide patents expire, and when can generic versions of Galantamine Hydrobromide launch?

Galantamine Hydrobromide is a drug marketed by Aurobindo Pharma, Barr, Impax Labs, Norvium Bioscience, Sun Pharm, Watson Labs, Hikma, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Rx, Dr Reddys Labs Ltd, Heritage Pharma, Mylan, Sandoz, Yabao Pharm, and Zydus Pharms Usa Inc. and is included in nineteen NDAs.

The generic ingredient in GALANTAMINE HYDROBROMIDE is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Galantamine Hydrobromide

A generic version of GALANTAMINE HYDROBROMIDE was approved as galantamine hydrobromide by BARR on August 28th, 2008.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GALANTAMINE HYDROBROMIDE?
  • What are the global sales for GALANTAMINE HYDROBROMIDE?
  • What is Average Wholesale Price for GALANTAMINE HYDROBROMIDE?
Summary for GALANTAMINE HYDROBROMIDE
Drug patent expirations by year for GALANTAMINE HYDROBROMIDE
Drug Prices for GALANTAMINE HYDROBROMIDE

See drug prices for GALANTAMINE HYDROBROMIDE

Recent Clinical Trials for GALANTAMINE HYDROBROMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt University Medical CenterPhase 1
Ortho-McNeil Neurologics, Inc.Phase 4
Duke UniversityPhase 4

See all GALANTAMINE HYDROBROMIDE clinical trials

Pharmacology for GALANTAMINE HYDROBROMIDE
Medical Subject Heading (MeSH) Categories for GALANTAMINE HYDROBROMIDE
Anatomical Therapeutic Chemical (ATC) Classes for GALANTAMINE HYDROBROMIDE
Paragraph IV (Patent) Challenges for GALANTAMINE HYDROBROMIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RAZADYNE ER Extended-release Capsules galantamine hydrobromide 16 mg and 24 mg 021615 1 2006-03-11
RAZADYNE ER Extended-release Capsules galantamine hydrobromide 8 mg 021615 1 2006-03-02
RAZADYNE Tablets galantamine hydrobromide 4 mg, 8 mg and 12 mg 021169 14 2005-02-28

US Patents and Regulatory Information for GALANTAMINE HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077590-001 May 29, 2009 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys Labs Ltd GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077593-001 Sep 11, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077589-003 Jun 22, 2009 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077603-002 Aug 28, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Yabao Pharm GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077604-001 Feb 6, 2009 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.